Table 1

a) Responders
	Sex	Age	PsA	Previous biological treatment	Current treatment	Baseline PASI	Weeks of treatment	PASI at the time of study
1.	M	66	no	no	infliximab + MTX 7.5	41.2	230	0
2.	M	58	no	efalizumab	infliximab	30.4	246	0
3.	M	56	no	etanercept	infliximab	13.8	118	0
4.	M	59	no	no	infliximab	12.0	62	0
5.	M	50	no	efalizumab	infliximab	10.2	158	0
6.	F	24	no	etanercept	infliximab	13.5	134	1.2
7.	M	60	yes	efalizumab	infliximab + MTX 15	41.1	316	0
8.	M	49	yes	no	infliximab+ MTX 10 + KS	10.2	230	0
9.	F	48	no	no	infliximab	22.0	54	1.2
10.	F	60	no	etanercept	infliximab	28.0	174	0
11.	M	41	no	no	infliximab	44.3	238	1.2
12.	M	34	no	no	infliximab	22.5	22	0
13.	M	63	no	no	infliximab + MTX 7.5	40.0	342	0
14.	M	32	no	efalizumab	infliximab	32.0	158	0
15.	M	49	no	efalizumab	infliximab	18.2	326	0
16.	M	62	no	ustekinumab	infliximab	12.6	62	1.2
17.	M	53	no	adalimumab	infliximab	59.0	46	2.7
b) Partial responders
	Sex	Age	PsA	Previous biological treatment	Current treatment	Baseline PASI	Weeks of treatment	PASI at the time of study
18.	F	37	yes	no	infliximab + KS	19.2	134	6
19.	M	53	no	etanercept, adalimumab	infliximab	11.0	22	3.6
20.	M	56	no	no	infliximab	31.1	30	10.2
21.	M	58	no	etanercept	infliximab	20.0	182	10.8
22.	M	55	yes	no	infliximab	10.0	30	2.7
23.	M	32	no	efalizumab	infliximab	20.0	166	5.4
24.	M	60	no	etanercept	infliximab	19.8	138	4.3
c) Non-responders
	Sex	Age	PsA	Previous biological treatment	Treatment	Baseline PASI	Weeks of treatment	PASI at the time of study
25.	F	54	no	etanercept	infliximab	10.8	166	4.6

Table 1: Basic characteristics of patients included in the study. PsA–psoriatic arthritis. M-male. F–female. KS–systemic corticosteroids. MTX–methotrexate.